SuperworthREGENXBIO EPS RGNX
Diluted earnings per share by quarter and over the last twelve months, from 2014.
- Last 12 months, to Jun 30, 2026
- −$3.79
- Latest quarter, Q2 FY26
- $0.43
- Fiscal year 2025
- −$3.76
REGENXBIO's earnings per share was −$3.79 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $0.43.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$3.76 | n/a |
| FY2024 | −$4.61 | n/a |
| FY2023 | −$6.03 | n/a |
| FY2022 | −$6.50 | −340% |
| FY2021 | $2.71 | n/a |
| FY2020 | −$3.00 | n/a |
| FY2019 | −$2.59 | −190% |
| FY2018 | $2.89 | n/a |
| FY2017 | −$2.47 | n/a |
| FY2016 | −$2.39 | n/a |
| FY2015 | −$5.90 | n/a |
| FY2014 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.43 | n/a | −$3.79 | |
| Q1 FY26 | −$1.72 | −1533% | −$5.60 | |
| Q4 FY25 | −$1.30 | n/a | −$3.76 | |
| Q3 FY25 | −$1.20 | n/a | −$3.47 | |
| Q2 FY25 | −$1.38 | n/a | −$3.44 | |
| Q1 FY25 | $0.12 | n/a | −$3.11 | |
| Q4 FY24 | −$1.01 | n/a | −$4.61 | |
| Q3 FY24 | −$1.17 | n/a | −$5.03 | |
| Q2 FY24 | −$1.05 | n/a | −$5.27 | |
| Q1 FY24 | −$1.38 | n/a | −$5.88 | |
| Q4 FY23 | −$1.43 | n/a | −$6.03 | |
| Q3 FY23 | −$1.41 | n/a | −$5.98 |
Against its peers
Companies in Biotechnology nearest REGENXBIO's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| RGNXREGENXBIO | −$3.79 | |
| MGTXMeiraGTx | $0.71 | |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| Peer median | $0.58 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on REGENXBIO
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.